Brief: Erasca Announces First Patient Dosed In Herkules-1 Phase 1B Trial

Erasca

20/12/2022 13:02

Dec 20 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA ANNOUNCES FIRST PATIENT DOSED IN HERKULES-1 PHASE
1B
TRIAL EVALUATING ERAS-007 AND ERAS-601 MAPKLAMP COMBINATION IN
RAS/MAPK PATHWAY-ALTERED SOLID TUMORS
    * ERASCA INC - PROMISING PRELIMINARY MONOTHERAPY DATA FOR
ERK1/2
INHIBITOR ERAS-007 AND SHP2 INHIBITOR ERAS-601 IN ADVANCED SOLID
TUMORS

Source text for Eikon:  ID:nGNX1l2Qxb 
Further company coverage:  ERAS.O 
 ((Reuters.Briefs@thomsonreuters.com;))